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Small ubiquitin-like modifiers play critical roles in the
DNAdamage response (DDR). To increase our under-
standing of SUMOylation in the mammalian DDR, we
employed a quantitative proteomics approach in or-
der to identify dynamically regulated SUMO-2 con-
jugates and modification sites upon treatment with
the DNA damaging agent methyl methanesulfonate
(MMS). We have uncovered a dynamic set of 20 upre-
gulated and 33 downregulated SUMO-2 conjugates,
and 755 SUMO-2 sites, of which 362 were dynamic
in response to MMS. In contrast to yeast, where a
response is centered on homologous recombination,
we identified dynamically SUMOylated interaction
networks of chromatin modifiers, transcription fac-
tors, DNA repair factors, and nuclear body com-
ponents. SUMOylated chromatin modifiers include
JARID1B/KDM5B, JARID1C/KDM5C, p300, CBP,
PARP1, SetDB1, and MBD1. Whereas SUMOylated
JARID1B was ubiquitylated by the SUMO-targeted
ubiquitin ligase RNF4 and degraded by the protea-
some in response to DNA damage, JARID1C was
SUMOylated and recruited to the chromatin to de-
methylate histone H3K4.
INTRODUCTION
Posttranslational modifications (PTMs) significantly increase the
functional repertoire of proteomes. PTMs range from small
chemical modifications such as phosphorylation, acetylation,
and methylation to small protein modifiers such as ubiquitin
and ubiquitin-like family members (Ubls). Ubls are covalently
attached to lysines in target proteins through an isopeptide
bond, and thereby regulate the functions of these proteins.More-
over, modification by Ubls is a reversible process and therefore
provides cells with a mechanism to facilitate a rapid response
to dynamic conditions. Conjugation and removal of Ubls is coor-
dinated by a subset of specialized and often context-specific
enzymes.
Small ubiquitin-likemodifiers (SUMOs) aremembers of theUbl
family and have been implicated in orchestration of biological1778 Cell Reports 10, 1778–1791, March 17, 2015 ª2015 The Authorprocesses ranging from control of cell-cycle progression and
transcriptional regulation to chromatin remodeling and DNA
repair (Flotho and Melchior, 2013; Hickey et al., 2012; Ulrich
and Walden, 2010; Vertegaal, 2011). Compared to ubiquitin,
the machinery responsible for SUMO conjugation and removal
consists of a relatively small subset of enzymes, even though
SUMOsmodify in the range of 1,500 proteins in mammalian cells
(Hendriks et al., 2014). Furthermore, whereas ubiquitin functions
in all cellular compartments, SUMOs are predominantly located
in the nucleus and enriched in Promyelocytic Leukemia (PML)
nuclear bodies, playing a pivotal role in the regulation of this
critical subcellular domain. SUMOs display some specificity in
conjugation, with the predominant consensus motif being [VIL]
KxE, although SUMOylation on alternate or non-consensus mo-
tifs also occurs (Matic et al., 2010).
Our knowledge on the coordination of the DNA damage
response by SUMOylation has significantly improved over the
last decade (Jackson and Durocher, 2013). As SUMOs are natu-
rally abundant in the nucleus, they provide an effective cellular
mechanism for regulating the function of proteins involved in
the response to DNA damage. A significant number of studies
have been published on SUMOylation with regard to regulating
singular DNA damage response proteins (Galanty et al., 2009;
Hoege et al., 2002; Jackson and Durocher, 2013; Morris et al.,
2009; Stelter and Ulrich, 2003; Ulrich and Walden, 2010).
Whereas insight into the direct mechanistic effect of SUMO
conjugation on a protein is highly interesting, there are cases
where the effect of deregulation of SUMOylation on a singular
target only causes a modest defect and does not always lead
to a significant phenotype (Silver et al., 2011). Instead, SUMOs
are likely to regulate the function of many proteins simulta-
neously, which altogether is required for efficient functioning of
the cell. Indeed, disruption of the SUMO machinery at the level
of conjugating and deconjugating enzymes leads to embryonic
lethality, associated with genome instability (Geiss-Friedlander
and Melchior, 2007).
Advances in the field of mass spectrometry and bio-infor-
matics have increasingly facilitated the system-wide study of
PTMs. Large studies on modifications such as phosphorylation,
acetylation, and ubiquitylation have been published, with many
thousands of target proteins being quantitatively investigated,
and tens of thousands specific conjugation sites being mapped
(Choudhary and Mann, 2010; Silva et al., 2013). Due to the rela-
tively low abundance of SUMOylation and purification challengess
of SUMO-conjugated proteins, SUMOs still elude in-depth inves-
tigation. Progress has been made in large-scale analysis of
SUMOylated proteins, especially through application of stable
isotope labeling of amino acids in culture (SILAC), allowing
SUMOylation to be quantitatively studied at the protein level
(Schimmel et al., 2014; Vertegaal, 2011; Yang et al., 2012).
More recently, there have been large advances in the identifica-
tion of SUMO-2 conjugation sites, allowing hundreds of these
sites to bemapped (Hendriks et al., 2014; Tammsalu et al., 2014).
We utilized a SUMOpurification method combining harsh lysis
with efficient and high-yield purification of SILAC-labeled FLAG-
SUMO-conjugated proteins (Schimmel et al., 2014), and addi-
tionally applied a label-free site-specificmethod for identification
of SUMO sites utilizing His10-tagged SUMO (Hendriks et al.,
2014). This combined methodology was employed to study the
role of SUMOylation in the cellular response to methyl methane-
sulfonate (MMS), a commonly utilized alkylating agent. MMS
provokes the formation of DNA adducts that impair replication
fork progression (Alabert et al., 2009; Va´zquez et al., 2008).
Recruitment of DNA repair proteins to these damaged replica-
tion forks is necessary to bypass the lesions (Gonza´lez-Prieto
et al., 2013).
RESULTS
A Strategy to Purify FLAG-SUMO-2 Conjugates
by Immunoprecipitation
SUMO-specific proteases (SENPs) are responsible for deconju-
gation of SUMOs from their target proteins. SUMO conjugates
are notoriously difficult to purify from cells due to the robustness
and high activity of SENPs upon cell lysis. To date, there are
no effective and cell-permeable SENP-specific inhibitors. Thus,
lysis of cells in standard buffers makes isolation of SUMO-conju-
gates difficult as SENPs are stable under a wide range of condi-
tions and act very swiftly and promiscuously to remove SUMOs
from all target proteins.
In order to study SUMOylated proteins, a common approach is
usage of an epitope-tagged exogenous SUMO in order to facili-
tate purification after lysis under highly denaturing conditions.
We utilized FLAG-tagged SUMO-2 stably expressed at near-
endogenous levels in HeLa cells (Figure 1A). Investigation of
the FLAG-SUMO-2 cell line by confocal fluorescent microscopy
revealed a proper nuclear localization of FLAG-SUMO-2, as well
as characteristic nuclear bodies scattered around the nucleus
(Figure 1B). SUMO-2, which is virtually identical to SUMO-3
(Wang andDasso, 2009), was chosen in the context of our exper-
iment because it is themost dynamic and abundant SUMO family
member (Saitoh and Hinchey, 2000).
SUMOylation Dynamics in Response to the DNA
Damaging Agent MMS
SUMOylation plays a key role in the DNA Damage Response
(DDR) (Jackson and Durocher, 2013); e.g., it was shown that
the SUMOylation system is required for cellular responses to
MMS (Hoege et al., 2002; Maeda et al., 2004). Despite the iden-
tification of a significant number of DDR components as SUMO
target proteins, global insight in SUMOylation dynamics in
response to DNA damage is limited.CellIn order to quantitatively detect changes in SUMOylation of
proteins during the DDR, we utilized a SILAC approach to apply
differential metabolic labeling to FLAG-SUMO-2 cell lines as well
as the parental HeLa cell line (Figure 1C). Subsequently, we
treated the FLAG-SUMO-2 cells with MMS and left another
pool of FLAG-SUMO-2 cells and the parental HeLa cells un-
treated, prior to lysis and subsequent immunoprecipitation of
FLAG-SUMO-2 (Figure 1D). Upon treatment with MMS, SUMO
nuclear bodies rapidly dispersed, indicating a role for the disso-
ciation of these SUMO-enriched nuclear bodies in response to
DNA damage (Figure 1B).
In addition to studying the changes in the SUMOylated prote-
ome at the protein level, we also investigated changes at the site-
specific level in response to MMS (Figure 1E). To this end, we
employed a label-free methodology utilizing a HeLa cell line sta-
bly expressing lysine-deficient His10-tagged Q87R SUMO-2
(Hendriks et al., 2014). In order to increase accurate quantitative
coverage of SUMOylation dynamics at the site-specific level, we
cross-matched peptides detected by MS2 in any replicate to all
others, through alignment of retention time and m/z characteris-
tics at the MS1 level (Figure 1E).
LC-MS Identification of Dynamically Regulated
SUMOylated Proteins in Response to DNA Damage
We identified 1,431 putative SUMO targets using the SILAC
approach and 844 putative SUMO targets using the label-free
approach. By overlapping proteins detected in both appro-
aches, we identified 317 SUMOylated proteins with very high
confidence (Figure 2A; Table S1). Furthermore, we mapped
SUMOylation sites in 194 of these proteins. In total, we mapped
755 SUMO sites (Table S2) in 352 proteins (Table S3).
We identified 20 proteins with upregulated SUMOylation and
33 proteins with downregulated SUMOylation in response to
MMS treatment (Figure 2B; Table S4). Proteins were only consid-
ered if they were enriched after purification from the FLAG-
SUMO-2 cell line as compared to the parental control cell line.
In order for proteins to be considered dynamic, we filtered for
a significant and consistent change across all proteomic ana-
lyses and replicates. We observed a notable correlation between
the SILAC and label-free approaches (Figure S1A), regardless of
different experimental setup.
Interestingly, while a modest decrease in the total SUMOy-
lated pool of proteins was observed, various SUMOylated
proteins were upregulated, including p300, CBP, PARP1, and
JARID1C (Figures 2B and S1B). One of the most striking
changes we observed was the downregulation of SUMOylated
demethylase JARID1B, whereas SUMOylation of the closely
related family member JARID1C was upregulated in response
to MMS.
At the sites level, 71 sites were observed to be upregulated in
response to MMS, whereas 291 sites were found to be downre-
gulated (Figure 2C; Table S5). We identified sites in 36 out of 53
of the dynamic SUMO targets and in general found site dy-
namics to closely match protein dynamics. Although more
downregulated sites were observed than upregulated sites,
several key DNA damage proteins such as BRCA1, Rap80,
MDC1, PARP1, and XPA were found to be increased for
SUMOylated.Reports 10, 1778–1791, March 17, 2015 ª2015 The Authors 1779
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Figure 1. Generation of Cell Lines Stably Expressing FLAG-Tagged SUMO-2 and Purification of FLAG-SUMO-2 Conjugates following MMS
Treatment
(A) HeLa cells were infected with a lentivirus encoding FLAG-SUMO-2. Cells stably expressing low levels of FLAG-SUMO-2 were selected by flow cytometry.
Total lysates were analyzed by immunoblotting to confirm the expression of FLAG-SUMO-2. Ponceau-S staining is shown as a loading control.
(B) Stable cell lines were investigated by z-stacked confocal fluorescent microscopy to confirm nuclear localization of FLAG-SUMO-2. Characteristic SUMO
nuclear bodies are indicated with arrows. Upon MMS treatment (0.02% for 90 min), SUMO nuclear bodies dispersed. Scale bars represent 5 mm.
(C) Schematic representation of the SILAC proteomics workflow. One set of parental HeLa cells and two sets of HeLa cells expressing FLAG-SUMO-2 were
differentially SILAC labeled (K0R0/K4R6/K8R10). One labeled FLAG-SUMO-2 set was treated with 0.02% MMS for 90 min. The experiment was repeated with
reversal of SILAC labels.
(D) Coomassie analysis of total lysate sample versus FLAG-purified SUMOylated proteins, prior to in-gel digestion and analysis by mass spectrometry.
(E) Schematic representation of the label-free proteomics workflow for identification of SUMO sites. Four sets of His10-SUMO-2-K0-Q87R cells were treatedwith
0.02% MMS for 90 min, and four sets were control treated, prior to SUMO site enrichment, identification, and quantification.
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We performed a comparison of all SUMOylated proteins and
sites we identified to other MS/MS studies (Becker et al., 2013;
Bruderer et al., 2011; Golebiowski et al., 2009; Hendriks et al.,
2014; Matic et al., 2010; Schimmel et al., 2014; Tammsalu
et al., 2014). Overall, 93% of the proteins we identified were pre-
viously reported in the literature, and 94% of the MMS-dynamic
subset (Figure S1C; Table S6). In addition, 92% of SUMOylated
proteins identified by site (Figure S1D; Table S6), and 86% of all
SUMOylation sites, were previously reported (Figure S1D; Table
S7). As such, the high accuracy of our combined approach is
demonstrated by re-identification of many known SUMO target
proteins.
Characterization of a SUMO-Regulated System-wide
Response to DNA Damage
Term enrichment analysis of SUMO-regulated proteins pro-
vided more insight into the dynamic regulation of the DNA dam-
age response by SUMO (Figure 2D). Proteins with increased
SUMOylation showed enrichment in categories such as signal
transduction in response to DNA damage, double-strand break
repair, and methyltransferase activity. Conversely, proteins with
decreased SUMOylation were found to be involved in regulation
of transcription, transcription cofactors, and awide range of chro-
matin modifications and organization. Overall, SUMO targets
were enriched for localization in nucleus and in the chromatin.
STRING network analysis of all SUMO-regulated proteins in
response to MMS identified 57% of these proteins to be known
or predicted interactors to each other (Figure 2E), giving strong
backing to the theory of dynamic regulation by SUMO of groups
of functionally related proteins (Johnson, 2004; Psakhye and
Jentsch, 2012). Addition of SUMO-2 itself to the cluster connects
70% of all proteins together (Figure S1E). Of special note is the
PML/CBP/p300/PARP1 main cluster, which functionally con-
nects 38% of all identified SUMO-regulated proteins to each
other. This cluster is composed of 12 up- and 8 downregulated
SUMOylated proteins, displaying SUMO’s ability to modulate
proteins in a balanced manner.
STRING network analysis of all proteins containing dynamic
SUMO sites linked 75% of these proteins together in one func-
tional cluster (Figure S1F). Many proteins that contain multiple
dynamic sites generally displayed the same dynamics for
all sites. However, certain proteins such as PML, TRIM24,
TRIM28, and TRIM33 contained sites that were inversely regu-
lated in response to MMS, indicative of the dynamic nature of
SUMO-2 modification.
Differential SUMOylation of Chromatin Modifiers
in Response to MMS
On further investigation of selected target proteins by immuno-
blotting, we confirmed the differential SUMO-regulation of these
proteins, as initially identified by mass spectrometry (Figure 3A).
P300 andCBP, two important transcriptional co-activators, were
found to be more highly SUMOylated in response to MMS. A
higher SUMOylation of these proteins is indicative of reduced
function, which would lead to overall transcriptional repression
(Girdwood et al., 2003). We verified the increase in Poly ADP-
Ribose Polymerase 1 (PARP-1) SUMOylation (Figure 3A) and
also observed a slight decrease in total SUMO (Figure 3B).CellStrikingly, we identified the histone 3 lysine 4 di- and tri-
methylation specific demethylases JARID1B and JARID1C as
being differentially regulated by SUMO in response to MMS (Fig-
ure 3A). Whereas JARID1C SUMOylation was increased after
MMS treatment, JARID1B SUMOylation was no longer detect-
able. Furthermore, upon confirmation that the upper band on
the immunoblot corresponded to full-length endogenous
JARID1B by small hairpin RNA (shRNA)-mediated knockdown
of the protein in HeLa and U2OS cells (Figure S2), we discovered
that the JARID1B protein was swiftly degraded in its entirety dur-
ing MMS treatment.
The SUMOylated form of Promyelocytic Leukemia (PML) pro-
tein, a tumor suppressor protein, has a key function in structuring
nuclear bodies (Ishov et al., 1999; Mu¨ller and Dejean, 1999;
Shen et al., 2006). We confirmed the rapid loss of SUMOylation
after MMS treatment by immunoblotting, and the dissociation
of PML nuclear bodies by confocal fluorescent microscopy (Fig-
ure 3C). We also verified the decreased SUMOylation of Methyl-
CpG-binding domain protein 1 (MBD1) after MMS treatment by
immunoblotting (Figure 3A).
SUMOylated JARID1B and PML Are Degraded by the
Ubiquitin-Proteasome in Response to MMS
We investigated the involvement of the ubiquitin-proteasome by
combining MMS treatment of cells with the proteasome inhibitor
MG132. For this purpose, we used a U2OS cell line stably ex-
pressing His10-SUMO-2 to investigate SUMOylated proteins.
In response to MMS, SUMOylated JARID1B and PML were
rapidly degraded, as observed earlier in HeLa cells (Figure 4).
When pre-treating cells with MG132 before addition of MMS,
the degradation of JARID1B protein was blocked entirely.
Furthermore, the degradation of SUMOylated JARID1B and
PML was prevented.
Degradation of SUMOylated JARID1B and PML
Is Controlled by the SUMO-Specific Ubiquitin E3
Ligase RNF4
RNF4 is a SUMO-specific ubiquitin E3 ligase that recognizes
poly-SUMOylated target proteins through its SUMO Interaction
Motifs (SIMs) and subsequently facilitates the ubiquitylation
and degradation of these proteins (Sun et al., 2007). We investi-
gated the involvement of RNF4 by using shRNA-mediated deple-
tion of endogenous RNF4 prior to MMS treatment (Figure 5A).
We observed an accumulation of highly SUMOylated PML
when depleting endogenous RNF4 prior to treatment with
MMS. When treating cells with arsenic trioxide as a control
(Tatham et al., 2008), PML was found to be more heavily poly-
SUMOylated, and additional depletion of endogenous RNF4 re-
sulted in a further increase of highly SUMOylated forms of PML.
Similarly, SUMOylated JARID1B was retained after MMS treat-
ment when endogenous RNF4 was depleted. In contrast to
PML, we observed no notable change in JARID1B’s SUMOyla-
tion state in response to arsenic treatment. Depletion of RNF4
did not further increase JARID1C SUMOylation in response to
MMS. We noted a considerable increase of these proteins
when endogenous RNF4 was depleted. RNF4 regulates many
poly-SUMOylated proteins, and its absence would result in an
accumulation of its SUMOylated targets.Reports 10, 1778–1791, March 17, 2015 ª2015 The Authors 1781
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Figure 3. Confirmation of Mass Spectrometry Results
(A) HeLa cells and HeLa cells stably expressing FLAG-SUMO-2 were either mock treated or treated with MMS. Cells were lysed, and FLAG-IP was performed to
enrichSUMOylatedproteins. Total lysatesandSUMO-enriched fractionswereanalyzedby immunoblotting toconfirmtheSUMOregulationof the indicatedproteins.
(B) Immunoblotting verification of overall level of SUMO-conjugated proteins in the total lysates and SUMO-enriched fractions after MMS treatment and FLAG-IP.
(C) Cell lines stably expressing FLAG-SUMO-2 were investigated by confocal fluorescent microscopy for the presence of PML nuclear bodies. Upon MMS
treatment, PML bodies rapidly dispersed. Scale bars represent 5 mm.Dissociation of PMLNuclear Bodies in Response toMMS
Treatment Is Modulated by SUMO-Specific Ubiquitin E3
Ligase RNF4
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Figure 4. SUMOylated JARID1B and PML Are Rapidly Degraded by
the Proteasome upon MMS Treatment
U2OS cells stably expressing His10-tagged SUMO-2 were treated with 0.02%
MMS for the indicated amount of time. One set of cells was additionally treated
with the proteasome inhibitor MG132 at 10 mM. Cells were lysed, and His10
pull-down was performed to enrich SUMOylated proteins. Total lysates and
SUMO-enriched fractions were analyzed by immunoblotting using antibodies
against JARID1B and PML. Ponceau-S staining was performed on total lysate
fractions as a loading control.
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depletion of endogenous RNF4 by shRNA-mediated knockdown
(Figure 5B). We additionally selected multiple fields in an unbi-
ased fashion and quantified cells and their respective PMLbodies
(Figure 5C). When RNF4was depleted in cells prior to MMS treat-
ment, as opposed to the control, the large majority of cells still re-
tained their PML bodies after 45 min of MMS treatment, and after
90 min over a quarter of all cells retained a moderate amount of
PML bodies. These findings show that PML bodies dissociate
through RNF4-mediated ubiquitylation and subsequent degrada-
tion of SUMOylated PML in response to MMS.
Cells Enter a Transcriptionally Repressed State
in Response to MMS Treatment
As JARID1B and JARID1C are H3K4me2/3-specific demethy-
lases, we investigated the effect of MMS on the global level of
the transcriptional activity markers H3K4me2 and -me3 in
U2OS cells (Figure 6A). We observed that, with increasing
amounts of DNAdamage induced by treating cells with increasing
dosage of MMS, the global H3K4me2 and H3K4me3 levels drop
in a dynamic fashion in concurrencewith the amount ofDNAdam-
age, indicating that the differential regulation of JARID1B and
JARID1C resulted in increased demethylase activity.
In these experiments, we also verified the levels of the tran-
scriptional repressive marks H3K9me2 and -me3, since our
screen also indicated the dynamic regulation by SUMOylation
of the H3K9 methylases SETDB1 and MBD1 (Figure 3A; Tables
S2 and S3). Interestingly, global levels of H3K9me2 and
H3K9me3 were elevated as more DNA damage is incurred.
Overall, our results show that SUMOylation orchestratesmultiple
histone demethylases and methylases in response to DNA dam-
age, resulting in a state of transcriptional inhibition, as cells are
likely to decrease transcriptional activity to prioritize DNA repair
processes (Svejstrup, 2010).
JARID1B Levels Are Regulated by RNF4 under Standard
Growth Conditions
We demonstrated that SUMOylated forms of JARID1B can be
stabilized in response to MMS by depletion of RNF4 (Figure 5A).
The effect of RNF4 depletion on the total levels of JARID1B was
further investigated through small interfering RNA (siRNA)-medi-
ated knockdown (Figure 6B).We observed a large increase in the
base level of JARID1B in both HeLa and U2OS cells in the
absence of RNF4. After 1 hr of MMS treatment, there is a stabi-
lization of JARID1B in response to RNF4 knockdown, although
eventually non-modified JARID1B is degraded after 2 hr of
MMS treatment. H3K4me3 was found to be decreased after
depletion of RNF4, which could be a direct result of stabilization
of JARID1B (Figure 6B). In response to MMS, however, a more
significant drop in H3K4me3 levels was observed, and even
though aggravated by absence of RNF4, the decline in
H3K4me3 was likely orchestrated by additional demethylases
other than JARID1B.
H3K4me2/3-Specific Demethylase JARID1C Is
Recruited to theChromatin in Response to DNADamage
Investigation of JARID1C total protein levels after MMS treat-
ment revealed no substantial decrease, as opposed to JARID1B.s
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In order to explain the decreased levels of H3K4me2/3, we stud-
ied the subcellular localization of these JARID1 family members
(Figure 6C). As anticipated, we found JARID1B to be located
exclusively in the chromatin-associated fraction prior to DNA
damage. Furthermore, MMS treatment resulted in a swift chro-
matin-associated loss of JARID1B as expected from the global
drop in JARID1B. Similar results were acquired in HeLa cells
(Figure S3B). Consistently, we found the known JARID1B targets
JUN andMCL1 to be upregulated in response toMMS treatment
by qPCR (Figure S3A).
Remarkably, we found JARID1C to be localized mainly in the
soluble nucleoplasmic fraction prior to DNA damage (Figure 6B).
It is therefore plausible to assume that JARID1C exists in amostly
inactive form in cells under normal conditions, whereas JARID1B
continuously modulates the H3K4me2/3 state of its targets.
Strikingly, upon MMS treatment of cells we found that JARID1C
is relocated from the nucleoplasmic fraction to the chromatin-
associated fraction, indicating an activation of this H3K4me2/3
demethylase in response to DNA damage (Figure 6B). Further-
more, the total level of JARID1C remained mostly unchanged,
indicative of a relocation of a considerable fraction of JARID1C.
Similar results were obtained in HeLa cells (Figure S3B).
We investigated the SUMOylation state of JARID1C in the
chromatin-associated fraction and found that there is a small
amount of SUMOylated JARID1C present at the chromatin
before MMS treatment (Figure S3C). Upon MMS treatment, the
amount of SUMOylated JARID1C in the chromatin-associated
fraction increased considerably, in line with the increase in
JARID1C SUMOylation in the total protein pool. Similar results
were found in HeLa cells stably expressing His10-SUMO-2 (Fig-
ure S3C). Our findings imply that the SUMOylation of JARID1C
may be a result of its localization to the chromatin, or conversely
may play a role in its localization to the chromatin.
In order to investigate the effect of RNF4 on the regulation and
localization of JARID1B and JARID1C in response to DNA dam-
age, we performed a cellular fractionation assay in combination
with shRNA-mediated RNF4 depletion and in response to MMS
treatment (Figure 6D). As before, we observed a stabilization of
total JARID1B by depletion of RNF4. Localization of JARID1C
from the soluble nucleoplasmic fraction to the chromatin did
not depend on the presence of RNF4. We further confirmed
that RNF4 had no effect on the localization of JARID1B and
JARID1C by siRNA-mediated depletion of RNF4 and cellular
fractionation (Figure S3D). As such, the stronger decline in
H3K4me3 by a combination of MMS treatment and RNF4 deple-
tion may be a result of both JARID1B and JARID1C actively de-
methylating their targets (Figure 6D).
JARID1C Demethylates Global H3K4me2 and H3K4me3
in Response to DNA Damage
In U2OS cells overexpressing GFP-JARID1C, we observed that
the protein localized exclusively to the nucleus, as anticipated
(Figure 7A). Overexpression of GFP-JARID1C by itself resulted
in a slight decrease of global H3K4me3. However, overexpres-
sion of GFP-JARID1B at similar or lower levels resulted in a
near complete removal of H3K4me3 (Figure S4), indicative of
efficient localization of JARID1B to the chromatin under regular
cell-culture conditions. Furthermore, MMS treatment of U2OSCellcells resulted in a similar slight decrease of global H3K4me3.
Strikingly, when cells overexpressing GFP-JARID1C were
treated with MMS, we observed a dramatic drop of H3K4me3
(Figure 7A). We propose that upon treatment with MMS, GFP-
JARID1C is recruited to the chromatin analogous to endogenous
JARID1C, where it then actively removes H3K4me3.
Overall, our study indicates that SUMOylation orchestrates a
complex network of chromatin modifiers to regulate transcrip-
tional responses to DNA damage (Figure 7B).
DISCUSSION
SUMO Orchestrates the Cellular Response to DNA
Damage
Small Ubiquitin-like Modifiers play critical roles in the DNA
Damage Response (Jackson and Durocher, 2013; Ulrich and
Walden, 2010). To increase our understanding of the roles of
SUMOylation in the DDR, we have performed a combined SILAC
and label-free quantitative proteomics approach to identify
dynamically regulated SUMO-2 conjugates and sites upon treat-
ment with MMS. We have uncovered a set of 20 SUMO-2 conju-
gates and 71 sites that were upregulated in response to MMS,
and 33 conjugates and 291 sites that were downregulated Iden-
tified dynamic SUMO target proteins included interaction net-
works of chromatin modifiers, transcription factors, DNA repair
factors, and nuclear body components.
SUMOCoordinates Global Transcriptional Repression in
Response to DNA Damage
Cells respond to DNA damaging agents by globally altering their
transcriptional programs (Fry et al., 2005). Transcriptome-wide
studies have indicated that around 30% of mRNAs are altered
in response to MMS treatment (Begley and Samson, 2004).
This response includes the downregulation of genes involved
in protein synthesis to enable cells to focus on nucleic acidmeta-
bolism. Moreover, genes involved in the DDR are upregulated in
response to MMS (Jelinsky and Samson, 1999).
Our results indicate that SUMO plays an important role in the
orchestration of global transcriptional reprogramming in
response to MMS at the chromatin level. First, trimethylation of
histone H3K4 is a key chromatin mark of active genes (Chi
et al., 2010) associated with SUMOylation (Neyret-Kahn et al.,
2013) and was found to be decreased upon MMS treatment.
Mechanistically, this could be explained by recruitment of
JARID1C to the chromatin uponMMS treatment to reduce global
H3K4me3. Our findings indicate a role for JARID1C in the DNA
damage response.
Second, global levels of the transcriptional repressive marks
H3K9me2/3 (Chi et al., 2010) were found to be increased upon
MMS treatment. Mechanistically, this could be explained
by reduced SUMOylation of Methyl-CpG-Binding domain 1
(MBD1) in response to MMS. MBD1 forms a repressive complex
with the methylase SETDB1 to facilitate methylation of H3K9,
and SUMOylation of MBD1 has been reported to counteract its
interaction with SETDB1 and thus prevent its repressive function
(Lyst et al., 2006). The decrease in MBD1 SUMOylation that we
observed in our study is therefore expected to increase the inter-
actionwith SETDB1, concomitantly increasing themethylation ofReports 10, 1778–1791, March 17, 2015 ª2015 The Authors 1787
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(A) U2OS cells were transfected with GFP-
JARID1C and either mock treated or treated with
0.02% MMS for 90 min. Subsequently, cells were
fixed and investigated by confocal fluorescent
microscopy to check for the presence of JARID1C
(GFP) and the level of H3K4me3. Scale bars
represent 25 mm.
(B) Schematic overview of the effect of SUMOy-
lation on various key proteins involved in the
cellular response to DNA damage and the down-
stream effect on chromatin remodeling and tran-
scriptional regulation.H3K9. We also discovered an increased SUMOylation of
SETDB1 itself.
Third, we observed increased SUMOylation of the acetyl trans-
ferases CBP and p300, which was previously shown to decrease
the activity of these proteins (Girdwood et al., 2003). CBP and
p300 acetylate all four core histones, which is expected to cause
nucleosome instability (Sterner and Berger, 2000). Interestingly,
in addition to histones, another target protein is (Poly [ADP-
ribose] Polymerase 1) PARP-1,which requires its acetylated state
in order to PARylate its targets (Messner et al., 2009), including
histone H3 (Messner et al., 2010), thus functioning as a transcrip-
tional co-activator by organizing a permissive chromatin environ-
ment. Correspondingly, we identified PARP1 itself to be increas-
ingly SUMOylated after MMS treatment, which has been implied
to further inhibit its acetylation by P300 (Messner et al., 2009), in1788 Cell Reports 10, 1778–1791, March 17, 2015 ª2015 The Authorsturn, leading to additional diminishment of
PARP1’s activity. The decrease of PARP1
activity would then lead to loss of histone
H3 PARylation, in turn, paving the way for
the JARID1 family members to demethyl-
ate H3K4me3 (Krishnakumar and Kraus,
2010), leading to inhibition of transcrip-
tion. Additionally, PARP1 plays a key
role in homologous recombination (Beck
et al., 2014).
Combined, orchestration of these
chromatin modifiers by SUMOylation
contributes to a transcriptional repressive
environment by decreasing H3K4me2/3,
increasing H3K9me2/3 and decreasing
histone acetylation. Although transcrip-
tional inhibition was the dominant effect
orchestrated by SUMOylation, it was not
an exclusive phenomenon as JUN and
MCL1 were upregulated (Figure S3A).
Mechanistically, this could be explained
by the degradation of JARID1B, since it
actively controls a set of cell-cycle and
DNA damage response proteins (Bueno
and Richard, 2013). Whether the regula-tion of JARID1B and 1C in response to MMS is a more general
feature of the DNA damage response remains to be addressed.
JARID1B and 1C deregulation has been associated with various
types of cancer (Kandoth et al., 2013; Mitra et al., 2011; Roesch
et al., 2008; Xiang et al., 2007).
SUMO Group Modification in Response to DNA Damage
STRINGanalysis revealed that over half of the identified SUMO-2
target proteins that were responsive to DNA damage are known
to functionally interact. Over one-third of all identified proteins
resided in one single interaction cluster. This most striking clus-
ter we identified contains many functionally relevant proteins
such as PML, SP100, TDG, CBP, P300, PARP1, TOPORS,
MDC1, HSF1, MITF, SETDB1, and MBD1, among others, only
highlighting a subsection from this cluster. Coordination of these
protein networks by SUMOylation is an efficient manner for rapid
regulation of functional protein groups via post-translational
modification. Group modification by SUMO in response to
MMS in yeast was described previously (Johnson, 2004; Psa-
khye and Jentsch, 2012) but differs from our findings as in yeast
the DNA damage response was centered around homologous
recombination, whereas in human cells we observed a response
tailored toward DNA repair, transcriptional regulation, and chro-
matin remodeling.
SUMO-Targeted Ubiquitin Ligases in the DNA Damage
Response
We have shown here that proteasomal degradation of SUMOy-
lated JARID1B and SUMOylated PML in response to MMS is
mediated by the SUMO-targeted ubiquitin ligase RNF4. Previ-
ously, theMediator of DNA damage checkpoint 1 (MDC1) protein
was identified as a SUMOylated target protein that is subse-
quently ubiquitylated by RNF4 in response to ionizing radiation
(Galanty et al., 2012; Luo et al., 2012; Vyas et al., 2013; Yin
et al., 2012). RNF4 ubiquitylated SUMOylated MDC1 leading to
its subsequent degradation by the proteasome, an event that
is necessary to facilitate proper progression of homologous
recombination repair. In our study, we also observed an increase
of MDC1 SUMOylation in response to MMS (Table S4).
Summary and Future Perspective
In summary, we have studied the role of SUMOylation in
response to DNA damage, uncovering a co-regulated group of
SUMO target proteins, including a significant number of chro-
matin modifiers that cooperate to decrease global transcription
upon DNA damage. Our study uncovers a tight link between
the role of SUMOylation in the DNA damage response and the
role of SUMOylation in transcriptional regulation, the two key
areas of SUMOylation research. Detailed functional analysis of
proteins identified in this project, and further studies on the role
of SUMO in response to different types of DNA damage, will un-
doubtedly further increase our insight in the role of SUMOylation
in the DNA damage response and genome stability.
EXPERIMENTAL PROCEDURES
Plasmids
Plasmids are described in the Supplemental Experimental Procedures.
Cell Culture and Cell-Line Generation
HeLa and U2OS cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% FBS and 100 U/ml penicillin and strep-
tomycin (Invitrogen). HeLa cells stably expressing FLAG-SUMO-2 were gener-
ated through lentiviral infection with a virus encoding FLAG-SUMO-2-IRES-
GFP. U2OS cells stably expressing His10-SUMO-2 were generated in a similar
fashion using a lentiviral construct carrying His10-SUMO-2-IRES-GFP. Two
weeks after infection, cells were fluorescence-sorted for a low expression level
of GFP using a FACSAria II (BD Biosciences). His10-SUMO-2-K0-Q87R cells
were described previously (Hendriks et al., 2014).
SILAC Labeling and MMS Treatment
HeLa cells were cultured in DMEM supplemented with 10% dialyzed FBS and
containing light ([12C6
14N2]lysine/[
12C6,
14N4]arginine), medium ([
2H4,
12C6,
14N2]
lysine/[13C6,
14N4]arginine), or heavy ([
13C6,
15N2]lysine/[
13C6,
15N4]arginine)
lysines and arginines. Light label is referred to as K0/R0, medium label asCellK4/R6, and heavy label as K8/R10. Cells were cultured in SILAC DMEM for
8 days, during which they were passaged twice, prior to treatment and lysis.
The SILAC MMS experiment was carried out in biological duplicate with a la-
bel-swap, with the MMS-treated FLAG-SUMO-2 cell line being heavy-labeled
and light-labeled in separate biological replicates, and the mock-treated
FLAG-SUMO-2 cell line being light-labeled and medium-labeled, respectively.
The HeLa parental control was included in the second replicate using heavy
label. The label-free MMS experiment was carried out in biological quadrupli-
cate. For proteomics, all MMS-treated cells were incubated with 0.02% MMS
for a duration of 90 min.
Primary Antibodies
Primary antibodies included the following: mouse a SUMO-2 (8A2, Abcam),
mouse a FLAG (M2, Sigma), mouse a PML (5E10, kind gift from Prof. R van
Driel, University of Amsterdam [Stuurman et al., 1992]), rabbit a JARID1B
(A301-813A, Bethyl Laboratories), rabbit a JARID1C (A301-035A, Bethyl
Labs), rabbit a p300 (a kind gift fromDr. A. Zantema, Leiden University Medical
Center [Ramos et al., 2010]), rabbit a CBP (A-22, Santa Cruz Biotechnology),
rabbit a H3K4me2 (C64G9, Cell Signaling Technology), rabbit a PARP1
(9542L, Cell Signaling Technology), mouse aMBD1 (IMG-306, IMGENEX), rab-
bit aH3K4me3 (C42D8, Cell Signaling Technology), rabbit aH3K9me2 (4658P,
Cell Signaling Technology), rabbit aH3K9me3 (07-442, Millipore), rabbit aHis-
tone H3 (06-755, Millipore), rabbit a RNF4 (raised against GST-RNF4 [Vyas
et al., 2013]), and mouse a GFP (11 814 460 001, Roche).
Mass Spectrometric and Bioinformatics Analysis
The mass spectrometry analysis and subsequent bioinformatics analyses are
described in the Supplemental Experimental Procedures.
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